NCT06930664

A Study of Sotatercept (MK-7962) in Healthy Females Administered as a Liquid Formulation in an Autoinjector Versus the Lyophilized Formulation (MK-7962-027)

A Phase 1 Clinical Study in Healthy Females of Nonchildbearing Potential to Compare the Pharmacokinetics of Sotatercept (MK-7962) Administered as a Liquid Formulation in an Autoinjector Versus the Lyophilized Formulation

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 146 (actual)
• Sponsor: Merck Sharp & Dohme LLC · Industry
• Sex: Female
• Age: 18 Years – 85 Years
• Healthy volunteers: Accepted

Summary

The goal of the study is to learn what happens to different forms of sotatercept medications in a healthy person's body over time. Researchers want to know if there is a difference in the healthy person's body when different forms of sotatercept medications are given.

Conditions

• Healthy

Interventions

Type	Name	Description
BIOLOGICAL	Sotatercept	Subcutaneous Injection
BIOLOGICAL	Sotatercept Autoinjector	Subcutaneous Auto Injection

Timeline

• Start date: 2025-05-16
• Primary completion: 2025-11-11
• Completion: 2025-11-25
• First posted: 2025-04-16
• Last updated: 2025-12-15

Locations

4 sites across 1 country: United States

Regulatory

• FDA-regulated drug study